This study was conducted to determine the relative risk of pneumonitis and pneumonia in patients with solid tumor treated with PD-1/PDL-1inhibitor or CTLA4 inhibitor alone or in combination. This evidence concerns the gene CTLA4 and susceptibility to pneumonia measurement.